ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q2 2023. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $22,778,939 | -57.7% | 180,857 | -68.6% | 0.37% | -61.6% |
| Q3 2023 | $53,884,014 | +4.9% | 575,438 | +0.0% | 0.97% | +11.5% |
| Q2 2023 | $51,357,395 | -38.8% | 575,432 | -26.5% | 0.87% | -43.6% |
| Q1 2023 | $83,936,105 | -12.2% | 782,840 | +0.0% | 1.54% | -18.3% |
| Q4 2022 | $95,592,250 | -22.8% | 782,709 | -34.7% | 1.88% | -22.6% |
| Q3 2022 | $123,809,000 | +11.1% | 1,199,000 | 0.0% | 2.44% | +2.2% |
| Q2 2022 | $111,459,000 | -28.6% | 1,199,000 | -9.8% | 2.38% | -2.5% |
| Q1 2022 | $156,022,000 | -33.7% | 1,329,432 | -24.0% | 2.44% | -18.7% |
| Q4 2021 | $235,246,000 | -15.6% | 1,748,648 | 0.0% | 3.01% | -18.2% |
| Q3 2021 | $278,717,000 | +24.7% | 1,748,648 | +2.9% | 3.68% | +22.4% |
| Q2 2021 | $223,457,000 | +2.1% | 1,698,648 | 0.0% | 3.00% | -7.5% |
| Q1 2021 | $218,922,000 | -23.0% | 1,698,648 | -0.3% | 3.24% | -25.6% |
| Q4 2020 | $284,218,000 | +7.7% | 1,704,148 | -0.3% | 4.36% | -15.6% |
| Q3 2020 | $263,864,000 | +4.3% | 1,709,848 | 0.0% | 5.16% | -6.0% |
| Q2 2020 | $252,887,000 | +32.2% | 1,709,848 | +0.7% | 5.50% | -11.3% |
| Q1 2020 | $191,285,000 | -19.1% | 1,698,648 | 0.0% | 6.19% | -7.0% |
| Q4 2019 | $236,316,000 | +44.4% | 1,698,648 | 0.0% | 6.66% | +23.2% |
| Q3 2019 | $163,614,000 | -16.4% | 1,698,648 | 0.0% | 5.41% | -9.1% |
| Q2 2019 | $195,599,000 | -2.2% | 1,698,648 | 0.0% | 5.95% | -13.6% |
| Q1 2019 | $199,931,000 | +87.9% | 1,698,648 | 0.0% | 6.88% | +46.0% |
| Q4 2018 | $106,420,000 | -2.8% | 1,698,648 | +10.0% | 4.71% | +17.2% |
| Q3 2018 | $109,472,000 | +18.7% | 1,544,900 | +11.4% | 4.02% | +5.0% |
| Q2 2018 | $92,263,000 | +5.9% | 1,387,000 | +4.1% | 3.83% | -6.2% |
| Q1 2018 | $87,148,000 | +63.3% | 1,332,540 | 0.0% | 4.08% | +46.6% |
| Q4 2017 | $53,382,000 | +22.3% | 1,332,540 | +10.6% | 2.78% | +12.4% |
| Q3 2017 | $43,665,000 | +145.8% | 1,204,540 | +88.2% | 2.48% | +123.8% |
| Q2 2017 | $17,766,000 | +157.8% | 640,000 | +160.1% | 1.11% | +142.5% |
| Q1 2017 | $6,891,000 | +48.7% | 246,100 | +7.5% | 0.46% | +51.0% |
| Q4 2016 | $4,635,000 | – | 229,000 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 4,185,342 | $582,265,000 | 17.66% |
| Sofinnova Investments, Inc. | 1,109,874 | $154,406,000 | 11.13% |
| Avoro Capital Advisors LLC | 1,865,000 | $259,459,000 | 7.62% |
| Eventide Asset Management | 1,698,648 | $236,316,000 | 6.66% |
| Orbimed Advisors | 3,343,100 | $465,092,000 | 6.64% |
| Logos Global Management LP | 179,898 | $25,027,000 | 6.17% |
| Ghost Tree Capital, LLC | 200,000 | $27,824,000 | 5.30% |
| Eversept Partners, LP | 202,894 | $28,226,613 | 4.98% |
| Camber Capital Management LP | 663,000 | $92,237,000 | 4.69% |
| Spyglass Capital Management LLC | 250,972 | $34,915,000 | 4.48% |